Evaluation of effect of As203 on cell growth, cell cycle and apoptosis in human leukemia cell line HL-60

International Journal of Hematology-Oncology and Stem Cell Research

Volumn 6, Issue 1, 2012, Pages 30-35

  Rostami, Shahrbanou ^a,b   Abroun, Saeid ^a   Alimoghaddam, Kamran ^b   Nourozinia, Mehrdad ^a   Chahardouli, Bahram ^c   Ghavamzade, Ardeshir ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; As203; Cell cycle

Indexed keywords

ARSENIC TRIOXIDE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN HL 60; CELLULAR DISTRIBUTION; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; M PHASE CELL CYCLE CHECKPOINT; PROMYELOCYTIC LEUKEMIA;

EID: 84862633987     PISSN: 17351243     EISSN: 20082207     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002 Jul 15;62(14):3893-903.
2. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease:past, present, and future. Leuk Res. 2004 Sep;28(9):891-900.
3. Gazitt Y, Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology. 2005 Jun;10(3):205-13.
4. Li L, Wang J, Ye RD, Shi G, Jin H, Tang X, et al. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J Cell Physiol. 2008 Nov;217(2):486-93.
5. Lin CP, Huang MJ, Chang IY, Lin WY. Successful treatment of all-trans retinoic acid resistant and chemotherapy naive acute promyelocytic patients with arsenic trioxide-two case reports. Leuk Lymphoma. 2000 Jun;38(1-2):191-4.
6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997 May 1;89(9):3354-60.
7. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999 Nov 15;94(10):3315-24.
8. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6 Suppl 2:3-10.
9. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006 Jan;17(1):131-4.
10. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front- line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011 Jul 10;29(20):2753-7.
11. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32.
12. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005 Dec 1;106(12): 3917-25.
13. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000 Jun 1;60(11):3065-71.
14. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009 Jun 25;113(26):6528-32.
15. Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, et al. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Ann Oncol. 2010 Sep;21(9):1884-90.
16. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60 (from a patient with acute promyelocytic leukemia. Blood. 1979 Sep;54(3):713-33.
17. Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol. 2002 Mar;116(3):555-63.
18. Vernhet L, Morzadec C, van Grevenynghe J, Bareau B, Corolleur M, Fest T, et al. Inorganic arsenic induces necrosis of human CD34-positive haematopoietic stem cells. Environ Toxicol. 2008 Apr;23(2):263-8.
19. Zhong F, Zhang S, Shao C, Yang J, Wu X. Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis. Pathol Oncol Res. 2010 Sep;16(3):413-20.
20. Shao QS, Ye ZY, Ling ZQ, Ke JJ. Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol. 2005 Jun 14;11(22):3451-6.
21. Chiu HW, Ho YS, Wang YJ. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin. J Mol Med (Berl). 2011 Sep;89(9):927-41.
22. Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias LC. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem. 2010 Sep 24;285(39):29989-97.
23. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999 Jan 1;93(1):268-77.
24. Li D, Morimoto K, Takeshita T, Lu Y. Arsenic induces DNA damage via reactive oxygen species in human cells. Environ Health Prev Med. 2001 Apr;6(1):27-32.
25. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989 Nov 3;246(4930):629-34.
26. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 2000 Oct;33(5):261-74.
27. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003 Jul;17(7):1333-7.
28. Huang MJ, Hsieh RK, Lin CP, Chang IY, Liu HJ. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma. 2002 Nov;43(11):2191-9.
29. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 2002 Sep; 62(3): 529-38.
30. Duan XF, Wu YL, Xu HZ, Zhao M, Zhuang HY, Wang XD, et al. Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chem Biol Interact. 2010 Jan 5;183(1):222-30.